Skip to content

COVID-19 Testing Pilot Study

Feasibility Testing of a New COVID-19 Testing Platform

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04843878
Enrollment
326
Registered
2021-04-14
Start date
2021-01-05
Completion date
2021-03-12
Last updated
2021-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus, Diagnoses Disease, Diagnostic Test, Routine, Rapid Coronavirus Test

Keywords

COVID-19, Detect, Pandemic, Symptomatic, Asymptomatic, Anterior Nares

Brief summary

The purpose of this study is to determine the reliability of a low-cost rapid diagnostic test for COVID-19. The method of the testing procedure uses electrochemistry to detect COVID-19 spike proteins within human samples. To test the effectiveness of this new method, patients will be recruited as they present for testing at ambulatory Penn testing sites. Patients will be asked to self-collect one anterior nares samples under the supervision of authorized study personnel.

Interventions

DIAGNOSTIC_TESTCOVID Detect

The study is determining the efficacy of a new rapid COVID testing method.

Sponsors

Benjamin S. Abella, MD, MPhil
CollaboratorUNKNOWN
Marcelo Der Torossian Torres, Ph.D.
CollaboratorUNKNOWN
Cesar De La Fuente, Ph.D.
CollaboratorUNKNOWN
University of Pennsylvania
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. The subject must be an adult (age\>17) and either sex. 2. Written informed consent must be obtained prior to study enrollment. a. A subject who is eighteen (18) years or older must be willing to give written informed consent and must agree to comply with study procedures. 3. Subject must be able to read and write in English.

Exclusion criteria

1. The subject is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic, drug, or device including either treatment or therapy. 2. The subject has previously participated in this research study.

Design outcomes

Primary

MeasureTime frameDescription
Device Accuracy - Positive and Negative Percentage3 MonthsThe accuracy of the new prototype testing method will be determined by comparing the prototype's result to the clinical gold standard PCR test. The accuracy will be determined by calculating the percentage of the test's ability to correctly identify both the presence and absence of virus compared to the PCR result for the positive and negative results.
Device Accuracy - False positive and False negative percentage3 MonthsThe accuracy of the test will also be determined based on the percentage of false-positives and false-negatives compared to the gold standard clinical PCR test.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026